In a report released today, Josh Jennings from TD Cowen maintained a Buy rating on Cerus (CERS – Research Report), with a price target of $5.00.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Josh Jennings has given his Buy rating due to a combination of factors that highlight Cerus’s strong financial performance and growth prospects. The company reported a 9% increase in product revenue for the fourth quarter, reaching $50.8 million, which aligns with its January preannouncement. This steady growth was primarily driven by the platelets business in both EMEA and North America.
Looking ahead, Cerus has reiterated its revenue guidance for 2025, anticipating product revenues between $194.0 million and $200.0 million, reflecting an 8% to 11% increase. The growth is expected to be fueled by the continued adoption of the INTERCEPT system among US platelet customers, international expansion, and increased uptake of the IFC offering. With the IFC sales starting strong, contributing $3.0 million in Q4 and $9.2 million for the year, Cerus aims to further capitalize on this momentum with a target of $12 million to $15 million in sales for 2025.
In another report released yesterday, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $4.00 price target.